Jaunalksne Inta, Brokāne Linda, Petroška Donatas, Rasa Agnija, Alberts Pēteris
AmberLife Cancer Clinic, Jūrmala, Latvia.
National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Am J Ophthalmol Case Rep. 2020 Jan 31;17:100615. doi: 10.1016/j.ajoc.2020.100615. eCollection 2020 Mar.
To describe a case of choroidal melanoma treated with Rigvir® virotherapy in an adjuvant setting.
A female patient born in 1956 presented with a small choroidal melanoma in October 2007. 34 months after transpupillary thermotherapy the state of her eye worsened until tumor growth was visualized. Despite photodynamic therapy and transpupillary thermotherapy the tumor continued to grow locally. In October 2016 enucleation was performed. Since gene expression profile testing disclosed a tumor (class 2) with a high risk of metastasis formation in 5 years, the patient sought options to prevent progression of the disease. In December 2016 virotherapy with Rigvir® was started with 3 administrations for 3 consecutive days. Therapy was continued once per week until March 2017, when the administrations were changed to once per month. The patient is being monitored by an ophthalmologist. She is stable with the virotherapy ongoing and magnetic resonance cholangiopancreatography (7 May 2018) and abdominal ultrasound (23 March 2019) imaging excludes metastasis formation. The quality of life is high.
To the best of our knowledge, this is the first documented case of uveal melanoma treatment with virotherapy as an adjuvant therapy. Considering the few if any available treatments and the encouraging results of the present treatment, virotherapy should be evaluated more extensively as a potential treatment of uveal melanoma.
描述1例脉络膜黑色素瘤在辅助治疗中接受Rigvir®病毒疗法的病例。
一名1956年出生的女性患者于2007年10月被诊断为患有小脉络膜黑色素瘤。经瞳孔温热疗法34个月后，其眼部状况恶化，直至观察到肿瘤生长。尽管进行了光动力疗法和经瞳孔温热疗法，肿瘤仍继续局部生长。2016年10月进行了眼球摘除术。由于基因表达谱检测显示肿瘤（2类）在5年内有高转移风险，患者寻求预防疾病进展的方法。2016年12月开始使用Rigvir®进行病毒疗法，连续3天给药3次。治疗持续至2017年3月，期间每周给药1次，之后改为每月给药1次。该患者由眼科医生进行监测。在持续进行病毒疗法期间，她的病情稳定，磁共振胰胆管造影（2018年5月7日）和腹部超声（2019年3月23日）成像排除了转移形成。生活质量较高。
据我们所知，这是首例记录在案的将病毒疗法作为辅助疗法治疗葡萄膜黑色素瘤的病例。鉴于可用治疗方法稀少，且当前治疗结果令人鼓舞，病毒疗法应作为葡萄膜黑色素瘤的一种潜在治疗方法进行更广泛的评估。
